http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Changing Frontiers and Invisible Politics in Northeast Asia: A Conversation with Tessa Morris-Suzuki
Tessa Morris-Suzuki 고려대학교 민족문화연구원 2018 Cross-Currents Vol.0 No.27
This is an edited and updated transcript of a November 2016 interview that was part of the Tianxia Podcast Series (http://www.chinoiresie.info/tessa-morris-suzuki-podcast-diamond-mountains/). The conversation transcribed here focuses on a discussion of Tessa Morris-Suzuki’s To the Diamond Mountains: A Hundred-Year Journey through China and Korea (2010), a travelogue based on a trip she took in 2009 to Northeast China, North Korea, and South Korea with the purpose of retracing the 1910 journey of the English adventurer and artist Emily Georgiana Kemp. We discuss the book in relation to the momentous transformations that have occurred over the long twentieth century in the areas visited by Kemp, and to the ways in which grassroots movements and new forms of survival politics are remaking Northeast Asia today.
THE SOUTHERN PLATEAU – A NATURAL OCEAN LABORATORY FOR CLIMATE TRENDS
Tessa Watson,Thomas Craig,Gary Griffith 국제과학영재학회 2010 APEC Youth Scientist Journal Vol.2 No.-
Many studies have investigated the effects of climate change on the atmosphere, but few have looked into how it is affecting the ocean. We chose to study the Campbell Plateau, an area of the southern ocean south-east of New Zealand. We utilised oceanographic data from NASA’s SeaWiFS satellite about this area of ocean, and we processed and graphed this data. We found that the southern ocean is heating up, the mixed layer depth is shallowing, primary productivity is decreasing and the type of phytoplankton in the ocean is changing.
Psilocybin, an Effective Treatment for Major Depressive Disorder in Adults - A Systematic Review
Tessa Watford,Naqash Masood 대한정신약물학회 2024 CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE Vol.22 No.1
Psilocybin is a classical psychedelic which has been utilised for healing purposes for millenia. However, with its classification as a Schedule I substance, research into this compound is scarce with few FDA-approved clinical studies. Despite this, profound findings into its antidepressant effects (largely through its action on 5-HT1a receptors) in mental illnesses such as major depressive disorder have rapidly increased interest back into their potential therapeutic benefits. This systematic review provides an analysis of the studies examining the clinical use of psilocybin for major depressive disorder. In total 6 studies were selected, including 319 participants, with half being randomised controlled trials and half open label trials. In every study psychological support was included as an integral part of the treatment. It was found that every study significantly favoured the use of psilocybin in reducing depressive symptoms, with few side effects. This gives psilocybin an advantage over commonly prescribed selective serotonin reuptake inhibitors (SSRIs), which carry more risk and cause more adverse effects. This drug therefore shows promise for being used as a clinical treatment for major depressive disorder, however future research should develop a paradigm for its use, with the timing of sessions and type of psychological support specified to allow for more precise analysis of the clinical effects of the drug. Additionally, more studies into its clinical efficacy are needed for appropriate detection of any publication bias. With this, psilocybin could prove to be revolutionary in treating depression and become an alternative medication to SSRIs.